Global Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market Report 2021


DUBLIN, December 09, 2021– (BUSINESS WIRE) – The report “Pharmaceutical Contract Development and Manufacturing Organization (CMO) Global Market Report 2021: COVID-19 Growth and Change to 2030” has been added to ResearchAndMarkets.com offer.

The global pharmaceutical contract development and manufacturing (CMO) organizations market is expected to grow from $ 97.38 billion in 2020 to $ 103.24 billion in 2021 at a compound annual growth rate (CAGR) of 6%. The market is expected to reach $ 149.44 billion in 2025 at a CAGR of 9.7%.

Major players in Pharmaceutical Contract Development and Manufacturing Organization (CMO) market are Recipharm AB, Pfizer Inc., Boehringer Ingelheim International GmbH., Aenova Group, Famar, Jubilant Life Sciences Limited, Catalent Pharma Solutions, Chemicals Limited , Dishman Pharmaceuticals and HAUPT Pharma AG.

The pharmaceutical contract development and manufacturing market includes sales of pharmaceutical contract development and manufacturing products and related services. Some pharmaceutical companies outsource the manufacturing of products under contract to focus on R&D, marketing and branding of their products. The pharmaceutical development and contract manufacturing market includes manufacturing companies that manufacture drugs and other pharmaceutical products for other pharmaceutical companies on a contract basis.

The Pharmaceutical Contract Development and Manufacturing Organization (CMO) market covered in this report is segmented by type into Active Pharmaceutical Ingredient (API) Manufacturing, Finished Dosage Formulation (FDF) Development and Manufacturing, Secondary Packaging. It is also segmented by preclinical research phase, phase I, phase II, phase III, phase IV.

The pharmaceutical contract development and manufacturing market is constrained by the low capacity to utilize manufacturing facilities. Capacity utilization is calculated taking into account the potential full capacity of the production plant. The misuse of the capacity of the production plant is due to the inefficiency of the various sub-processes in the production line, resulting in low production.

Low production results in low revenue generation for the production unit, affecting the entire pharmaceutical contract development and manufacturing market. Therefore, the underutilization of the production plant capacity negatively affects the pharmaceutical contract development and manufacturing market.

The growth of the pharmaceutical contract development and manufacturing market is driven by increasing demand for drugs across the world.

The high prevalence of diseases and the need for a longer lifespan have increased the demand for drugs leading pharmaceutical companies to increase the production of existing drugs and to increase investments in their R&D to promote the development of new drugs. This prompts pharmaceutical companies to collaborate with contract manufacturing organizations (CMOs) to reduce operating costs, thereby increasing the demand in the pharmaceutical contract development and manufacturing market.

Companies in the pharmaceutical contract development and manufacturing market invest in acquiring and forming alliances with other companies in the market. Pharmaceutical contract manufacturing and development companies follow the trend of mergers and acquisitions in order to expand their reach in the global market to meet customer needs, increase their production capacities while maintaining profitability and ” have access to the latest technologies and new services. High levels of M&A activity are driving consolidation of contractual service providers.

Main topics covered:

1. Summary

2. Characteristics of Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market

3. Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market Trends and Strategies

4. Impact of COVID-19 on the organization of development and manufacturing of pharmaceutical contracts (CMO)

5.Size and Growth of Pharmaceutical Contract Development and Manufacturing (CMO) Organizations Market

5.1. Historical Pharmaceutical Contract Manufacturing and Development Organization (CMO) Global Market, 2015-2020, in USD Billion

5.1.1. Market pilots

5.1.2. Market restrictions

5.2. Global Pharmaceutical Contract Development and Manufacturing Organization (CMO) Organization Market Forecast, 2020-2025F, 2030F, in USD Billion

5.2.1. Market pilots

5.2.2. Market restrictions

6. Pharmaceutical Contract Development and Manufacturing Organizations (CMOs) Market Segmentation

6.1. Global Pharmaceutical Contract Development and Manufacturing (CMO) Organization Market, Segmentation by Type, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

6.2. Global Pharmaceutical Contract Development and Manufacturing (CMO) Organization Market, Segmentation by Research Phase, History and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

  • Preclinical

  • Phase I

  • Phase II

  • Phase III

  • Phase IV

7. Regional and Country Analysis of Pharmaceutical Contract Development and Manufacturing Organization (CMO) Market

7.1. Global Pharmaceutical Contract Development and Manufacturing (CMO) Organization Market, Divided by Region, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

7.2. Global Pharmaceutical Contract Development and Manufacturing (CMO) Organization Market, Divided by Country, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, in USD Billion

Companies mentioned

  • Recipharm AB

  • Pfizer Inc.

  • Boehringer Ingelheim International GmbH.

  • Aenova Group

  • Famar

  • Jubilant Life Sciences Limited

  • Catalent Pharma Solutions

  • Limited chemicals

  • Dishman Pharmaceuticals

  • HAUPT Pharma SA

  • Kemwell Pvt. Ltd.

  • Nipro Corp.

  • NextPharma

  • Royal DSM SA

  • Althea Technologies

  • Thermo Fisher Scientific Inc.

  • Lonza Group Ltd.

  • AbbVie Inc.

  • Consort Medical plc

  • Almac Group

  • Siegfried Holding AG

  • Evonik Industries SA

  • Vetter Pharma International GmbH

For more information on this report visit https://www.researchandmarkets.com/r/20i36r

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211209005546/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Director
[email protected]
For EST office hours, call 1-917-300-0470
For USA / CAN call toll free 1-800-526-8630
For GMT office hours, call + 353-1-416-8900


Comments are closed.